Ziprasidone for maintenance treatment of bipolar I disorder in adults

Bibliography

• Angst J. Epidemiology of the bipolar spectrum. Encephale 1995;21(SI 6):37-42
   PubMed Web of Science ®Google Scholar
• Berk M, Dodd S, Berk L, Opie J. Diagnosis and management of patients with bipolar disorder in primary care. Br J Gen Pract 2005;55:663-6
   Web of Science ®Google Scholar
• Hirschfeld RM, Cass AR, Holt DC, Carlson CA. Screening for bipolar disorder in patients treated for depression in a family medicine clinic. J Am Board Fam Pract 2005;18:233-9
   PubMedGoogle Scholar
• Dubovsky SL, Dubovsky AN. Concise guide to mood disorders. American Psychiatric Press, Washington, DC; 2002
   Google Scholar
• Bipolar Disorder Work Group. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159:1-50
   Web of Science ®Google Scholar
• Dubovsky SL. Clinical guide to psychotropic medications. WW Norton, New York; 2005
   Google Scholar
• Ketter TA, Agid O, Kapur S, Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. J Psychiatr Res 2010;44:8-14
   PubMed Web of Science ®Google Scholar
• Brambilla P, Barale F, Soares JC. Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacology 2003;166:315-22
   PubMed Web of Science ®Google Scholar
• Bauer M, Mitchner L. What is a ‘mood stabilizer’? An evidence-based response. Am J Psychiatry 2004;161:3-18
   PubMed Web of Science ®Google Scholar
• Ehret MJ, Levin GM. Long-term use of atypical antipsychotics in bipolar disorder. Pharmacotherapy 2006;26:1134-47
   PubMed Web of Science ®Google Scholar
• Licht RW, Vestergaard P, Brodersen A. Long-term outcome of patients with bipolar disorder commenced on lithium prophylaxis during hospitalization: a complete 15-year register-based follow-up. Bipolar Disord 2008;10:79-86
   PubMed Web of Science ®Google Scholar
• Licht RW, Vestergaard P, Brodersen A. Long-term outcome of patients with bipolar disorder commenced on lithium prophylaxis during hospitalization: a complete 15-year register-based follow-up. Bipolar Disord 2008;10:79-86
   PubMed Web of Science ®Google Scholar
• Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropharmacology 2011;36:375-89
   Google Scholar
• Dubovsky SL, Dubovsky AN. Psychotropic drug prescriber's survival guide: ethical prescribing in the age of big pharma. W.W. Norton, New York; 2007
   Google Scholar
• Rybakowski JK. Long-term pharmacological treatment of bipolar disorders. Neuroendocrinol Lett 2007;28(Suppl 1):71-93
   PubMed Web of Science ®Google Scholar
• Malhi GS, Adams D, Cahill C, The management of individuals with bipolar disorder. A review of the evidence and its integration into clinical practice. Drugs 2009;69:2063-101
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Shirzadi AA, Filkowski MM. Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder. Med J Med 2008;10:2-11
   Google Scholar
• Calabrese JR, Bowden C, Sachs G, A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64:1013-24
   PubMed Web of Science ®Google Scholar
• Macfadden W, Alphs L, Haskins JT, A randomized, double-blind, placebo-controlled trial of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 2009;11:827-39
   PubMed Web of Science ®Google Scholar
• Vieta E, Suppes T, Eggens I, Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder. J Affective Disord 2008;109:251-63
   PubMed Web of Science ®Google Scholar
• Quiroz J, Yatham LN, Palumbo JM, Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010;68:156-62
   PubMed Web of Science ®Google Scholar
• Kauer-Sant'Anna M, Bond DJ, Lam RW, Yatham LN. Functional outcomes in first-episode patients with bipolar disorder: a prospective study from the Systematic Treatment Optimization Program for Early Mania project. Compr Psychiatry 2009;50:1-8
   PubMed Web of Science ®Google Scholar
• Tohen M, Sniadecki J, Sutton VK, Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder. J Clin Psychopharmacol 2009;29:520-8
   PubMed Web of Science ®Google Scholar
• Keck PEJ, Calabrese J, McIntyre RS, Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68:1480-91
   PubMed Web of Science ®Google Scholar
• Savas HA, Yumru M, Kaya MC, Selek S. Atypical antipsychotics as ‘mood stabilizers’: a retrospective chart review. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1064-7
   PubMed Web of Science ®Google Scholar
• Keck PE, Ice K. A 3-week, double-blind, randomized trial of ziprasidone in the acute treatment of mania. Present at the 40th Annual NCDEU Meeting; June 2000; Boca Raton, Florida, USA
   Google Scholar
• Potkin SG, Keck PE, Segal S, Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005;25:301-10
   PubMed Web of Science ®Google Scholar
• Scherk H, Pajonik G, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania. A systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007;64:442-55
   PubMed Web of Science ®Google Scholar
• Vieta E, Ramey T, Keller D, Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol 2010;24:547-58
   PubMed Web of Science ®Google Scholar
• Stahl S, Lombardo I, Loebel A, Mandel FS. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies. J Affective Disord 2010;122:39-45
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Schaffer A, Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder. Bipolar Disord 2009;11:225-55
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL, editors, Goodman and Gilman's the pharmacological basis of therapeutics. McGraw-Hill, New York; 2010; chapter 18
   Google Scholar
• Bowden CL, Vieta E, Ice KS, Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010;71:130-7
   PubMed Web of Science ®Google Scholar
• Citrome L. Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults. Expert Rev Neurother 2010;10:1031-7
   PubMed Web of Science ®Google Scholar
• Kim E, Maclean R, Ammerman D, Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis. Clin Ther 2009;31:836-48
   PubMed Web of Science ®Google Scholar
• Keck PEJ, Versiani M, Warrington L, Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania. J Clin Psychiatry 2009;70:844-51
   PubMed Web of Science ®Google Scholar
• Warrington L, Keck PEJ, Potkin S, Efficacy and safety of ziprasidone in bipolar disorder: long-term data. Presented at the 44th Annual Meeting of the New Clinical Drug Evaluation Unit; June 2004, Phoenix, Arizona, USA
   Google Scholar
• Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven culprits and suspects. Curr Drug Saf 2010;5:97-104
   PubMedGoogle Scholar
• Heinrich TW, Biblo LA, Schneider J. torsades de pointes associated with ziprasidone. Psychosomatics 2006;47:264-8
   PubMed Web of Science ®Google Scholar
• Alipour A, Cruz R, Lott RS. Torsade de pointes after ziprasidone overdose with coingestants [Letter]. J Clin Psychopharmacol 2010;30:76-7
   PubMed Web of Science ®Google Scholar
• Troller JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009;23:477-92
   PubMed Web of Science ®Google Scholar
• Edwards SJ, Smith CJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Clin Ther 2009;31:1345-59
   PubMed Web of Science ®Google Scholar
• Baptista T, ElFakih Y, Uzcategui E, Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 2008;22:477-95
   PubMed Web of Science ®Google Scholar
• Allen MH, Hirschfeld RMA, Wozniak PJ, Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006;163:272-5
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, McElroy SL, The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry 1999;45:953-8
   PubMed Web of Science ®Google Scholar
• Taylor MJ, Goodwin GM. Long-term prophylaxis in bipolar disorder. CNS Drugs 2006;20:303-10
   PubMed Web of Science ®Google Scholar